Avidity Partners Management LP Chemo Centryx, Inc. Transaction History

Avidity Partners Management LP

$1.63 Billion
Q3 2024

Shares

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$15.36 - $27.51 $18 Million - $32.3 Million	-1,175,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$22.22 - $39.12 $11.8 Million - $20.8 Million	530,600 Added 82.34%	1,175,000 $29.5 Million
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $11.8 Million - $26.1 Million	644,400 New	644,400 $23.5 Million
Q2 2021 Aug 16, 2021	SELL	$9.59 - $50.88 $9.02 Million - $47.9 Million	-940,800 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$49.53 - $68.4 $9.1 Million - $12.6 Million	183,800 Added 24.28%	940,800 $48.2 Million
Q4 2020 Feb 16, 2021	BUY	$47.25 - $65.16 $35.8 Million - $49.3 Million	757,000 New	757,000 $46.9 Million
Q3 2020 Nov 16, 2020	SELL	$46.35 - $61.69 $29.9 Million - $39.8 Million	-645,800 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$38.58 - $65.07 $15.8 Million - $26.7 Million	409,800 Added 173.64%	645,800 $37.2 Million
Q1 2020 Jun 17, 2020	BUY	$32.73 - $50.78 $7.72 Million - $12 Million	236,000 New	236,000 $9.48 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.